Advanced Solid Tumors
Conditions
Keywords
EMD 640744, Montanide, Advanced solid tumours
Brief summary
To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide® ISA 51 VG with regard to immunological efficacy. The primary target variable is the immune response as assessed by ELISPOT before and until week 17 after vaccination with EMD 640744 in Montanide® ISA 51 VG.
Interventions
BIOLOGICALEMD 640744
EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
OTHERMontanide ISA 51 VG
Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
Sponsors
Merck KGaA, Darmstadt, Germany
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female subjects ≥18 years of age * Signed written informed consent * Histologically or cytologically documented metastatic or locally advanced survivin-expressing solid tumor for which no established therapy exists * Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic, or laboratory criteria established for the given tumor entity * Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7 assessed by HLAgenotyping * ECOG performance status of ≤1, estimated life expectancy of at least 3 months * Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x 10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L * Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN * Adequate renal function defined by a serum creatinine ≤2 x ULN * Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels ≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN) * Effective contraception for female and male subjects if the risk of conception exists
Exclusion criteria
* Treatment in another clinical study within the past 30 days prior to the first administration of study treatment * Previous treatment with an investigational anticancer vaccine * Requirement of concurrent treatment with a nonpermitted drug * Active significant autoimmune disease (with the exception of vitiligo) * Receipt of allogeneic stem cell transplantation * Significant acute or chronic infections (e.g. viral hepatitis, HIV) * Primary brain tumors and brain metastases (with the exception of brain metastases that are stable after irradiation or surgically resected brain metastases if subjects have been asymptomatic for ≥6 months) * Rapidly progressive disease (e.g. tumor lysis syndrome) * Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy), immunotherapy or any investigational drug within 30 days before the start of study treatment * Pregnancy or lactation * Active drug or alcohol abuse * Known hypersensitivity to the study treatment or any of its components * Any significant disease that, in the Investigator's opinion, should exclude the subject from the study; for questions about this criterion, the Investigator should contact the sponsor. * Persisting toxicity related to prior therapy ≥grade 2 National Cancer Institute-Common Terminology Criteria For Adverse Events version 3.0 * Legal incapacity or limited legal capacity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with Montanide® ISA 51 VG with regard to immunological efficacy | 1-4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety and tolerability of different doses of EMD 640744 in Montanide® ISA 51 VG in terms of laboratory parameters and adverse event profile. | 3 months |
| To assess the clinical efficacy in terms of the overall response, progression-free survival time, and survival time. | 3 months |
Outcome results
None listed